Despite significant advances in treatments, ovarian cancer (OC) remains one of the most prevalent and lethal gynecological cancers in women. The frequent detection at the advanced stages has contributed to low survival rates, resistance to various treatments, and disease recurrence. Thus, a more effective approach is warranted to combat OC. The cytokine Interleukin-6 (IL6) has been implicated in various stages of OC development. High IL6 levels are also correlated with a lower survival rate in OC patients. In this current review, we summarized the pivotal roles of IL6 in OC, including the initiation, development, invasion, metastasis, and drug resistance mechanisms. This article systematically highlights how targeting IL6 improves OC outcomes by altering various cancer processes and reports the ongoing clinical trials that would further shape the IL6-based targeted therapies. This review also suggests how combining IL6-targeted therapies with other therapeutic strategies could further enhance their efficacy to combat OC.
尽管治疗手段已取得显著进展，卵巢癌仍是女性中最常见且致命的妇科恶性肿瘤之一。由于多数病例确诊时已至晚期，导致患者生存率低下、易产生多药耐药并常出现疾病复发。因此，亟需探索更有效的卵巢癌防治策略。细胞因子白细胞介素-6（IL6）被证实参与卵巢癌发展的多个阶段，其高表达水平与患者较低生存率密切相关。本综述系统阐述了IL6在卵巢癌发生、发展、侵袭、转移及耐药机制中的关键作用，重点解析靶向IL6如何通过调控肿瘤进程改善临床预后，并汇总了正在进行的相关临床试验进展。文章进一步提出，将IL6靶向治疗与其他治疗策略相结合，有望显著提升卵巢癌综合治疗效果。
肿瘤(癌症)患者之家